254 related articles for article (PubMed ID: 24287186)
1. Effect of pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) on outpatient antimicrobial purchases: a double-blind, cluster randomised phase 3-4 trial.
Palmu AA; Jokinen J; Nieminen H; Rinta-Kokko H; Ruokokoski E; Puumalainen T; Borys D; Lommel P; Traskine M; Moreira M; Schuerman L; Kilpi TM
Lancet Infect Dis; 2014 Mar; 14(3):205-12. PubMed ID: 24287186
[TBL] [Abstract][Full Text] [Related]
2. Vaccine effectiveness of the pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against clinically suspected invasive pneumococcal disease: a cluster-randomised trial.
Palmu AA; Jokinen J; Nieminen H; Syrjänen R; Ruokokoski E; Puumalainen T; Moreira M; Schuerman L; Borys D; Kilpi TM
Lancet Respir Med; 2014 Sep; 2(9):717-27. PubMed ID: 25127244
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: a cluster randomised trial.
Palmu AA; Jokinen J; Borys D; Nieminen H; Ruokokoski E; Siira L; Puumalainen T; Lommel P; Hezareh M; Moreira M; Schuerman L; Kilpi TM
Lancet; 2013 Jan; 381(9862):214-22. PubMed ID: 23158882
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of pneumococcal Haemophilus influenzae protein D conjugate vaccine against pneumonia in children: A cluster-randomised trial.
Kilpi TM; Jokinen J; Puumalainen T; Nieminen H; Ruokokoski E; Rinta-Kokko H; Traskine M; Lommel P; Moreira M; Ruiz-Guinazu J; Borys D; Schuerman L; Palmu AA
Vaccine; 2018 Sep; 36(39):5891-5901. PubMed ID: 30145098
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the indirect impact of the 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine in a cluster-randomised trial.
Rinta-Kokko H; Palmu AA; Ruokokoski E; Nieminen H; Moreira M; Schuerman L; Borys D; Jokinen J
PLoS One; 2022; 17(1):e0261750. PubMed ID: 34986178
[TBL] [Abstract][Full Text] [Related]
6. Vaccine-preventable disease incidence of pneumococcal conjugate vaccine in the Finnish invasive pneumococcal disease vaccine trial.
Palmu AA; Jokinen J; Nieminen H; Rinta-Kokko H; Ruokokoski E; Puumalainen T; Moreira M; Schuerman L; Borys D; Kilpi TM
Vaccine; 2018 Mar; 36(14):1816-1822. PubMed ID: 29503110
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of the 10-valent pneumococcal conjugate vaccine among girls, boys, preterm and low-birth-weight infants - Results from a randomized, double-blind vaccine trial.
Nieminen H; Rinta-Kokko H; Jokinen J; Puumalainen T; Moreira M; Borys D; Schuerman L; Palmu AA
Vaccine; 2019 Jun; 37(28):3715-3721. PubMed ID: 31122856
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of the Ten-valent Pneumococcal Conjugate Vaccine Against Tympanostomy Tube Placements in a Cluster-randomized Trial.
Palmu AA; Jokinen J; Nieminen H; Rinta-Kokko H; Ruokokoski E; Puumalainen T; Traskine M; Moreira M; Borys D; Schuerman L; Kilpi TM
Pediatr Infect Dis J; 2015 Nov; 34(11):1230-5. PubMed ID: 26284652
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial.
Tregnaghi MW; Sáez-Llorens X; López P; Abate H; Smith E; Pósleman A; Calvo A; Wong D; Cortes-Barbosa C; Ceballos A; Tregnaghi M; Sierra A; Rodriguez M; Troitiño M; Carabajal C; Falaschi A; Leandro A; Castrejón MM; Lepetic A; Lommel P; Hausdorff WP; Borys D; Ruiz Guiñazú J; Ortega-Barría E; Yarzábal JP; Schuerman L;
PLoS Med; 2014 Jun; 11(6):e1001657. PubMed ID: 24892763
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against all respiratory tract infections in children under two years of age.
Karppinen S; Toivonen L; Schuez-Havupalo L; Teros-Jaakkola T; Waris M; Auranen K; Palmu AA; Peltola V
Vaccine; 2019 May; 37(22):2935-2941. PubMed ID: 31027929
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine against acute otitis media and nasopharyngeal carriage in Panamanian children - A randomized controlled trial.
Sáez-Llorens X; Rowley S; Wong D; Rodríguez M; Calvo A; Troitiño M; Salas A; Vega V; Castrejón MM; Lommel P; Pascal TG; Hausdorff WP; Borys D; Ruiz-Guiñazú J; Ortega-Barría E; Yarzabal JP; Schuerman L
Hum Vaccin Immunother; 2017 Jun; 13(6):1-16. PubMed ID: 28368738
[TBL] [Abstract][Full Text] [Related]
12. Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled trials.
Leach AJ; Wilson N; Arrowsmith B; Beissbarth J; Mulholland EK; Santosham M; Torzillo PJ; McIntyre P; Smith-Vaughan H; Chatfield MD; Lehmann D; Binks M; Chang AB; Carapetis J; Krause V; Andrews R; Snelling T; Skull SA; Licciardi PV; Oguoma VM; Morris PS
Lancet Infect Dis; 2022 Sep; 22(9):1374-1387. PubMed ID: 35772449
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness of the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D-Conjugated Vaccine (PHiD-CV) Against Carriage and Acute Otitis Media-A Double-Blind Randomized Clinical Trial in Finland.
Vesikari T; Forsten A; Seppä I; Kaijalainen T; Puumalainen T; Soininen A; Traskine M; Lommel P; Schoonbroodt S; Hezareh M; Moreira M; Borys D; Schuerman L
J Pediatric Infect Dis Soc; 2016 Sep; 5(3):237-248. PubMed ID: 27125273
[TBL] [Abstract][Full Text] [Related]
14. Impact of the 10-valent pneumococcal conjugate vaccine on antimicrobial prescriptions in young children: a whole population study.
Eythorsson E; Sigurdsson S; Hrafnkelsson B; Erlendsdóttir H; Haraldsson Á; Kristinsson KG
BMC Infect Dis; 2018 Oct; 18(1):505. PubMed ID: 30286726
[TBL] [Abstract][Full Text] [Related]
15. Direct and Indirect Effectiveness of the 10-Valent Pneumococcal Conjugate Vaccine Against Carriage in a Cluster Randomized Trial.
Palmu AA; Toropainen M; Kaijalainen T; Siira L; Lahdenkari M; Nieminen H; Syrjänen RK; Kilpi TM; Jokinen J
Pediatr Infect Dis J; 2017 Dec; 36(12):1193-1200. PubMed ID: 28737627
[TBL] [Abstract][Full Text] [Related]
16. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study.
Prymula R; Peeters P; Chrobok V; Kriz P; Novakova E; Kaliskova E; Kohl I; Lommel P; Poolman J; Prieels JP; Schuerman L
Lancet; 2006 Mar; 367(9512):740-8. PubMed ID: 16517274
[TBL] [Abstract][Full Text] [Related]
17. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity.
Bermal N; Szenborn L; Chrobot A; Alberto E; Lommel P; Gatchalian S; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S89-96. PubMed ID: 19325451
[TBL] [Abstract][Full Text] [Related]
18. 10-Valent pneumococcal non-typeable
Oguoma VM; Wilson N; Mulholland K; Santosham M; Torzillo P; McIntyre P; Smith-Vaughan H; Balloch A; Chatfield M; Lehmann D; Binks MJ; Chang A; Carapetis J; Krause V; Andrews R; Snelling T; Licciardi P; Morris P; Leach AJ
BMJ Open; 2020 May; 10(5):e033511. PubMed ID: 32448790
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
[TBL] [Abstract][Full Text] [Related]
20. Anamnestic immune response in 3- to 4-year-old children previously immunized with 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine as 2-dose or 3-dose priming and a booster dose in the first year of life.
Silfverdal SA; Skerlikova H; Zanova M; Papúchová D; Traskine M; Borys D; Schuerman L
Pediatr Infect Dis J; 2011 Sep; 30(9):e155-63. PubMed ID: 21572373
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
